INA-RESPOND: a multi-centre clinical research network in Indonesia by Muhammad Karyana et al.
Karyana et al. Health Research Policy and Systems  (2015) 13:34 
DOI 10.1186/s12961-015-0024-9COMMENTARY Open AccessINA-RESPOND: a multi-centre clinical
research network in Indonesia
Muhammad Karyana1*, Herman Kosasih2, Gina Samaan3, Emiliana Tjitra1, Abu Tholib Aman4, Bachti Alisjahbana5,
Fatmawati6, M. Hussein Gasem7, Mansyur Arif8, Pratiwi Sudarmono9, Suharto10, Tuti P. Merati11, Clifford Lane12,
Siswanto1 and Sophia Siddiqui12Abstract
Nationally representative observational and translational research is needed to address the public health challenges
in Indonesia due to the geographic disparity, recently decentralized health system, and diverse infectious disease
priorities. To accomplish this, the Indonesian Ministry of Health in collaboration with the US National Institute of
Health has established INA-RESPOND (Indonesia Research Partnership on Infectious Disease) – a clinical research
network comprising 9 referral hospitals, 7 medical faculties, and 2 research centres across Indonesia. The network
provides a forum to conduct research at a national scale and to address scientific questions that would be difficult
to address in smaller research settings. Further, it is currently conducting multi-centre research on the etiologies of
fever, sepsis, and tuberculosis. There are opportunities to leverage existing network resources for other public health
research needs. INA-RESPOND is an Indonesian-led network in a country with diverse population groups and public
health needs which is poised to collaborate with researchers, universities, donors, and industry worldwide. This paper
describes the network and its goals and values, as well as the management structure, process for collaboration, and
future vision.
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Historically, Indonesian collaborations on health re-
search have resulted in landmark findings and impact on
public health. Such collaborations include Indonesia’s
contribution to the global eradication of smallpox
through the development of the smallpox recognition
card in 1968, which was adopted by the World Health
Organization and distributed worldwide [1], a vitamin A
supplementation study that commenced in Indonesia in
the 1970s, which established the link between vitamin A
deficiency and childhood morbidity and mortality and
which resulted in intervention policies [2–5], and the
hepatitis B vaccine field trial in 1987 that demonstrated
effective integration of the vaccine into the Expanded
Program on Immunization schedule to streamline vac-
cine delivery [6]. These examples illustrate Indonesia’s* Correspondence: mkaryana@gmail.com
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research collaborations both domestically and inter-
nationally. Indonesia is also working on incorporating
research into its national agenda, where health research
is governed by several regulations. These include regula-
tions about shipment of clinical specimens and bio-
logical materials, data sharing, intellectual property
rights, health research as a part of the national health
system, transfer of technology, research results and pub-
lication, and community involvement, as well as more
recently the requirement to register clinical research.
Infectious disease research and surveillance is managed
by the Ministry of Health (MoH), Ministry of Research
and Technology, and Ministry of Education. Research and
surveillance under the MoH are conducted by three
government agencies: (1) the National Institute of Health
Research and Development (NIHRD), (2) the Directorate
General of Disease Control and Health Environment, and
(3) the Directorate General of Medical Services. Research
at the Ministry of Research and Technology is mostly con-
ducted by the Eijkman Institute for Molecular Biology,article distributed under the terms of the Creative Commons Attribution License
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lic health faculties.
However, given Indonesia’s diverse geography, vari-
ation in population health, relatively recent decentralized
health system, and the varied infectious disease profile, a
nationally cohesive effort is needed to successfully ad-
dress major health and infectious disease-related issues.
Such a national forum would have the added advantages
of bringing together researchers and helping them
network within and outside the country, as well as build
internal capacity. Additionally, it would be an invaluable
resource in the face of a future emerging infectious dis-
ease threat.
Recognizing this, NIHRD engaged in a partnership
with the United States National Institutes of Allergy and
Infectious Disease (NIAID) within the National Insti-
tutes of Health (NIH) to develop a network that could
potentially become a leading scientific collaboration in
the country to address questions of national and global
impact and to enhance the capacity for implementation
research [7]. Since the MoH budget for research is lim-
ited (44 million US dollars in 2014) [8] and the priority
is not for conducting clinical research, this partnership
is advantageous as it can attract additional research
funding by providing potential collaborators a well-
developed infrastructure and facilities.
This paper describes the establishment of the INA-
RESPOND network, its key goals, challenges, and current
and future research.Indonesia research partnership on infectious diseases
(INA-RESPOND)
Initial discussions to develop the network began in
2007 at the request of the Minister of Health of
Indonesia at the time. In 2011, a Steering Committee
was established to determine the initial framework and
subsequently Ministerial and NIHRD decrees were is-
sued to help with formalizing the structural integration
of the network within the existing health framework of
the country under the MoH. Presently, INA-RESPOND
comprises 7 medical faculties and their 9 corresponding
hospitals as well as the Eijkman Institute, located in 7
large cities on Java, Bali, and Sulawesi islands (Figure 1),
under the coordination of NIHRD. The NIAID and the
United States Centers for Disease Control and Prevention
(US CDC) are collaborating partners within the network.
The mission of the network is to build a sustainable and
well-recognized research network that is able to conduct
high-quality infectious disease research in order to im-
prove the health of the people of Indonesia and to be
beneficial to the international community. The network
has a strategic plan and scientific agenda based on input
from multiple stakeholders.Goals and values of the network
INA-RESPOND is committed to becoming a regional
leader in clinical research excellence. The network is
focused on three main goals. The first is to generate
new knowledge on infectious diseases in the areas of
pathogenesis, treatment, and prevention, and to ensure
that relevant results are disseminated to public health
officials so that there is real impact on policies. To
accomplish this, the network has a scientific agenda
focused on the national infectious disease health prior-
ities as determined by the MoH. Secondly, there is a
keen awareness that long term sustainability can only
be achieved by establishing research infrastructure em-
bedded within the current system, providing appropri-
ate training and designating adequate human resources.
INA-RESPOND supports a model of full time dedicated
and well-trained research staff to assist busy investi-
gators so that research can be integrated in busy
clinical environments. Finally, the network hopes to
develop, implement, and maintain strong internal
and financial management and research operations
and practices to ensure quality research can be sup-
ported by well-organized, coordinated, and compre-
hensive mechanisms.
The network is committed to conducting innovative,
scientifically-sound, excellent, and ethical research, and
is responsive to the health priorities in Indonesia. INA-
RESPOND members work on the principles of team-
work based on trust, respect, transparency, good com-
munication, collaboration, and shared responsibility.
Anticipating centrality towards the most established
members, which is commonly found [7], INA-RESPOND
is enhancing the research and laboratory capacities in all
the sites in order for sites to take turns as the principal in-
vestigators, and sites are able to perform standard labora-
tory assays.
Organizational structure
To achieve a truly national research network, a com-
prehensive organizational structure was developed to
include major stakeholders in the national research
and public health community (Figure 2). The Advisory
Committee is comprised of members from the Re-
search and Technology Ministry, Directorate-General
of NIHRD, Directorate-General of Disease Control
and Environmental Health, Directorate-General of
General Medical Services, and MoH expert on Health
Technology and Globalization. This committee pro-
vides guidance and input on the development and
support for the implementation of scientific activities
within INA-RESPOND and ensures concurrence with
national priorities.
The Governing Board is currently comprised of
members from the two agencies engaged in a
Figure 1 The distribution of INA-RESPOND sites.
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NIHRD, and the US NIAID, as well as the Chair and
Vice Chair of the Steering Committee. It is tasked
with ensuring that national health priorities are
translated into the research agenda and are in line
with Advisory Committee suggestions. It is alsoFigure 2 The organizational structure of INA-RESPOND.instrumental in identifying funding sources for the
network and approving additional partners. The
Steering Committee of the network has representatives
of each participating hospital and institution, US
NIAID, and CDC, and manages a day to day
governance of the network, planning network activities,
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projects, reviewing progress of the network, and identify-
ing new partners.
Financial and technical support for the network
comes from the NIHRD under the MoH and the US
NIAID under the Department of Health and Human
Services. Additionally, all partners contribute resources at
their sites so that research is integrated within the hospi-
tals. Unlike other collaborations or networks, which are
often donor driven [7], all the strategic decisions are made
by the Steering Committee and Governing Board, in
which the donors have equal vote with other members.Current capabilities and functions
The INA-RESPOND secretariat is located at the
NIHRD and directed by the Chair of the Steering
Committee. It is the central operations and coordinat-
ing centre of the network and provides all support
needed to the sites and the investigators in conduct-
ing research protocols. The secretariat supports and
assists investigators in the development of protocols
and study documents and provides regulatory support,
trainings and monitoring, data management and ana-
lysis, centralized specimen repository, and laboratory
support. The independent scientific advisory commit-
tee reviews network protocols and provides sugges-
tions to ensure they are scientifically sound. The
INA-RESPOND data safety and monitoring board
provides oversight to interventional clinical trials.
In keeping with the commitment that research cap-
acity must be developed nationally, the sites are an inte-
gral part of this effort. The network has provided initial
infrastructure, including laboratory information manage-
ment system software, office and laboratory supplies,
and freezers to store the specimens. Each site has Good
Clinical Practice and Good Laboratory Practice trained
staff dedicated to research and fully engaged in research
activities.Research implementation and current studies
As INA-RESPOND aims to answer questions based
on national health priorities, studies are conducted in
several sites to ascertain adequate representation of
the diverse demographical population. The network hopes
to expand in the future to include additional regions of
the country.
Research priorities identified and proposals received
are evaluated by the Steering Committee based on
country priorities as outlined by the MoH, potential
impact, capacity building elements, current capabil-
ities, and resource allocation expected from the net-
work. Selected ideas are forwarded to the Governing
Board for development prior to protocol. INA-RESPONDis preparing guidelines that describe these procedures for
potential collaborators as well as network members.
Protocols are reviewed by a scientific review commit-
tee at the NIHRD, followed by the Research Ethics
Committee/Institutional Review Board of record. To fa-
cilitate regulatory approvals, INA-RESPOND has devel-
oped reliance agreements between multiple Institutional
Review Boards to circumvent the need for multiple
approvals.
The first study of the network was developed with
two clear goals: to understand the etiologies of fever re-
quiring hospitalization so that areas of future research
could be identified and to establish clinical research in-
frastructure. The second study is collaboration with the
South East Asia Infectious Disease Clinical Research
Network to determine the etiologies, management, and
outcomes of sepsis and severe sepsis. Subsequent stud-
ies that are being developed are directly based on several
key priority areas of the MoH, which are tuberculosis and
HIV. The tuberculosis study aims to estimate the propor-
tion of multi-drug resistant tuberculosis in naïve and
previously treated patients, treatment outcomes, and
factors associated with these outcomes. The HIV cohort
study aims to collect epidemiological, clinical, and labora-
tory data from HIV patients throughout Indonesia using a
nationally standardized form.
Challenges
INA-RESPOND presented a unique approach to re-
search in Indonesia. As a first step, it was very im-
portant to engage stakeholders, researchers, national
health programs, and policymakers. Given that the
more common paradigm was of externally sponsored
research, it was important to encourage clinicians and
health policymakers to identify research priorities in
Indonesia and enhance the understanding that the
sustainability of the network depended on their own
active and continued participation. Engaging busy cli-
nicians in all research processes, from the preparation
of study protocols to publication, and recruiting full-
time research assistants at the sites that were inter-
ested in a research career were also priorities.
To respond to these, INA-RESPOND engaged in meet-
ings with stakeholders and developed an Advisory
Committee (as described above). On an ongoing basis,
the network holds regular trainings, workshops, and
seminars to build trust by involving and regularly up-
dating all parties on the network activities. The net-
work also provides opportunities for members to
travel to national and international research conferences in
areas of interest, holds regular Steering Committee meet-
ings, and issues a newsletter to review network progress.
Researchers, stakeholders, and research assistants are en-
gaged in development of research concepts and protocols.
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master and doctorate degrees.
Future network vision and collaborations
Developing a network requires collaboration and part-
nership at many different levels. Key to success is devel-
oping trust within the research community in Indonesia
and internationally. INA-RESPOND does not wish to be
seen as a collaboration of a select group of scientists but
wishes to be a support and resource for all investigators
in Indonesia and globally. The network is committed to
identifying and establishing new collaborations and part-
nerships that can enhance its mission. The eventual goal
would be for researchers to be able to submit proposals
to the network and, if approved, the network would pro-
vide support in part or complete so that investigators
can leverage network resources rather than investing in
these individually. It would also enable investigators to
envision research questions that could be of much larger
national significance and on a much larger scale than
could be accomplished by a single hospital or centre.
The network aims to establish clinical research facil-
ities across the country to enable readiness in the event
of emerging infectious disease transmission. Once re-
search facilities exist they can be leveraged for non-
infectious disease research as well. While research on
infectious diseases is the current research focus of the
network, INA-RESPOND is also interested in collab-
orating in non-infectious and chronic diseases since
the threat of these is also emerging [9]. A soon to
commence study will include a collaboration with the US
National Cancer Institute of the National Institutes of
Health to evaluate smoking as a risk factor in diseases.
The establishment of a specimen bio-repository is also
a valuable asset for the country. These specimens may
be utilized in the future to conduct research based on
new findings or emerging research needs.
The network believes that, to be true to its goals of
building research capacity, it must provide resources for
new and young investigators, such as trainings in manu-
script and grant writing, ethics, and eventually Masters
and PhD programs, so that a constant infusion of new
and well trained investigators can be maintained.
Conclusion
INA-RESPOND is Indonesia’s first clinical research net-
work supported by the MoH. The aim is to conduct trans-
lational and clinical research and to prevent and treat
infectious diseases based on national concerns and in
alignment with MoH priorities. It is intended that the re-
search conducted by this network will support the devel-
opment of public health policies and build sustainable
research capacity within Indonesia. Multiple funding
streams will be key to ensuring financial strength andsustainability. Future plans include expansion to add-
itional sites so that optimal geographical and demographi-
cal representation can be achieved and engagement with
new collaborators, including industry and other sponsors,
in order to achieve the network mission of improving the
health of the people of Indonesia and the international
community.
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